12:00 AM
Nov 21, 2011
 |  BioCentury  |  Emerging Company Profile

Kareus: Linking up in AD

Kareus creates NCE for Alzheimers by linking compounds for simultaneous dosing

Kareus Therapeutics S.A. is using its Karlect linker technology to generate new chemical entities by covalently linking two compounds for simultaneous dosing in a target tissue.

Kareus had its genesis in a 2009 decision by Dr. Reddy's Laboratories Ltd. to drop work on small molecule drug discovery. But Dr. Reddy's founder and Chairman K. Anji Reddy believed the technologies were still worth pursuing, so he founded and financed Kareus to develop the Karlect technology along with a more traditional medicinal chemistry drug discovery program.

While Kareus has not disclosed details of the chemistry, Uday Saxena, head of R&D strategy, said the linkers can be either amino acids, fatty acids or short chain acids, "depending on what we want to accomplish."


Read the full 593 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >